03.01.2021 - By Mark Ebell and Michael Wilkes
Dr. Ebell and Dr. Wilkes discuss the POEM titled ' SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status '